Zai Lab And Innoviva Specialty Therapeutics Receives NMPA Approval For XACDURO (Sulbactam-Durlobactam) For Hospital-Acquired And Ventilator-Associated Pneumonia Caused By Acinetobacter Baumannii-Calcoaceticus Complex In China

5/20/24 12:40:14 AM ET

$INVA

$ZLAB

Biotechnology: Pharmaceutical Preparations

Health Care

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $INVA alert in real time by email

Drug-resistant Acinetobacter baumannii is a growing global health threat and high priority pathogen needing new antibiotics, according to World Health Organization
China NMPA approval based on comprehensive clinical data demonstrating robust activity of SUL-DUR against carbapenem-resistant bacterial strains
In China, it is estimated there are approximately 300,000 cases of Acinetobacter infections and approximately 74% of them are carbapenem-resistant

Get the next $INVA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$INVA
$ZLAB

Company	Date	Price Target	Rating	Analyst
Innoviva Inc. $INVA	6/18/2024		Overweight	Cantor Fitzgerald
Zai Lab Limited $ZLAB	12/14/2023	$47.50	Overweight	Morgan Stanley
Zai Lab Limited $ZLAB	8/10/2023	$70.00	Overweight	Cantor Fitzgerald
Innoviva Inc. $INVA	7/20/2022	$16.00	Neutral	Goldman
Zai Lab Limited $ZLAB	3/2/2022	$194.00 → $102.00	Outperform	SVB Leerink
Innoviva Inc. $INVA	2/23/2022	$10.00 → $12.00	Underweight	Morgan Stanley
Innoviva Inc. $INVA	2/11/2022	$28.00	Buy	EF Hutton
Zai Lab Limited $ZLAB	1/21/2022	$64.00	Outperform	Macquarie

More analyst ratings

$INVA
$ZLAB
Press Releases

Fastest customizable press release news feed in the world

Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)
Zai Lab (("Zai Lab", NASDAQ:ZLAB, HKEX: 9688)) and Pfizer (("Pfizer", NYSE:PFE) announced today a strategic collaboration for the novel antibacterial drug XACDURO® (sulbactam-durlobactam) in mainland China. Pfizer's affiliated companies will be exclusively authorized to undertake and perform certain commercialization activities for XACDURO® in mainland China. Through this collaboration, Zai Lab will leverage the industry-leading commercialization infrastructure of Pfizer's affiliated companies in the anti-infective therapeutic area to help accelerate access to this important therapy for patients in need in mainland China. The period of collaboration is for the imported product through Novem
11/21/24 4:00:00 AM ET
$PFE
$ZLAB
Biotechnology: Pharmaceutical Preparations
Health Care
Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
Zai Lab Limited ("Zai Lab" or the "Company") (NASDAQ:ZLAB, HKEX: 9688)), an innovative, commercial-stage biopharmaceutical company, today announced the anticipated closing of its previously announced underwritten public offering of 7,843,137 American depositary shares ("ADSs"), each representing ten ordinary shares of the Company, at a price of US$25.50 per ADS. In addition, Zai Lab today announced that the underwriters in the offering fully exercised their option to purchase an additional 1,176,470 ADSs at the public offering price, less underwriting discounts and commissions. The sale of additional ADSs pursuant to the exercise of the option to purchase additional ADSs is expected to clos
11/18/24 9:15:00 AM ET
$ZLAB
Biotechnology: Pharmaceutical Preparations
Health Care
Zai Lab Announces Pricing of Public Offering of American Depositary Shares
Zai Lab Limited ("Zai Lab" or the "Company") (NASDAQ:ZLAB, HKEX: 9688)), an innovative, commercial-stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 7,843,137 American depositary shares ("ADSs"), each representing ten ordinary shares of the Company, at a price of US$25.50 per ADS. The gross proceeds to Zai Lab from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $200 million. Subject to customary closing conditions, the underwriters expect to deliver the ADSs against payment to the purchasers on or about November 18, 2024, on a "T+2" basis. In addition, Zai
11/14/24 7:43:00 PM ET
$ZLAB
Biotechnology: Pharmaceutical Preparations
Health Care

$INVA
$ZLAB
Leadership Updates

Live Leadership Updates

Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D
Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) announced today that following a distinguished career, Harald Reinhart, M.D., President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases (NSAiID) of Zai Lab, will retire at the end of June, after which he will serve as a senior advisor for the Company. Rafael Amado, M.D., President, Head of Global Oncology Research and Development of Zai Lab, will expand his role and assume responsibility for all of the Company's Global R&D upon Dr. Reinhart's retirement. "Harald has devoted nearly 50 years to treating patients, first as a physician and later discovering and developing innovative therapies to bring to patients in
6/11/24 4:05:00 PM ET
$ZLAB
Biotechnology: Pharmaceutical Preparations
Health Care
Innoviva Appoints Stephen Basso as Chief Financial Officer
Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" and "the Company"), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced the appointment of Stephen Basso as its Chief Financial Officer, effective August 21, 2023. "We are excited to welcome Stephen to our executive leadership team and believe the Company will benefit greatly from his background and experience," said Pavel Raifeld, Chief Executive Officer of Innoviva. "I look forward to working with Stephen to advance our strategy and create shareholder value." Mr. Basso brings more than 30 years of experience in the financial services industry and financial leadership in the pharmaceutical ind
8/25/23 4:52:00 PM ET
$INVA
Biotechnology: Pharmaceutical Preparations
Health Care
Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics
Signs new $25 million credit agreement and extension of existing secured convertible credit agreement Appoints world‐renowned healthcare leader Dr. Deborah L. Birx as Chief Executive Officer MARINA DEL REY, Calif., July 11, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen‐specific bacteriophage therapeutics for antibiotic‐resistant and difficult‐to‐treat bacterial infections, today announced that it has entered into a credit and security agreement with Innoviva Strategic Opportunities LLC, a wholly‐owned subsidiary of Innoviva, Inc. (NASDAQ:INVA) (collectively, "Innoviva"). The gross proceeds of t
7/11/23 8:00:00 AM ET
$ARMP
$INVA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations

Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates
Strong growth in net product revenue of 47% y-o-y to reach $101.8 million for the third quarter of 2024 Positive China bridging study of KarXT in schizophrenia; expected regulatory submission in early 2025 Global Phase 1 data of ZL-1310 (DLL3 ADC) suggests best-in-class potential in extensive-stage SCLC Three product launches in mainland China expected by the end of 2024, and up to four potential regulatory submissions to the NMPA in the next six months Strong balance sheet with a cash position1 of $716.1 million as of September 30, 2024, compared to $730.0 million as of June 30, 2024 Conference call and webcast today, November 12, at 8:00 a.m. ET (9:00 p.m. HKT) Zai Lab L
11/12/24 6:30:00 AM ET
$ZLAB
Biotechnology: Pharmaceutical Preparations
Health Care
Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress
Core royalty platform continued strong performance, receiving GSK royalties of $60.5 million with 6% year-over-year growth Innoviva Specialty Therapeutics' (IST) marketed portfolio achieved U.S. net product sales of $19.7 million, reflecting 68% year-over-year growth Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the third quarter ended September 30, 2024, and highlighted select corporate achievements. "For the
11/6/24 4:05:00 PM ET
$INVA
Biotechnology: Pharmaceutical Preparations
Health Care
ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer
-- Objective response rate (ORR) of 74% across all tested dose levels of ZL-1310 in patients with recurrent extensive-stage small cell lung cancer (SCLC) -- Favorable pharmacokinetics (PK) and safety profile support continued evaluation of ZL-1310 as a single agent and in combination for the treatment of extensive-stage SCLC in recurrent and first-line therapy -- Zai Lab to host conference call and webcast to discuss data on October 24, 2024, at 8:30 a.m. ET, following presentation of the data at ENA Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today presented data from the ongoing global Phase 1a/1b study of ZL-1310, a potential best-in-class next-generation antibody-drug conjugate (ADC)
10/24/24 5:15:00 AM ET
$ZLAB
Biotechnology: Pharmaceutical Preparations
Health Care

Zai Lab And Innoviva Specialty Therapeutics Receives NMPA Approval For XACDURO (Sulbactam-Durlobactam) For Hospital-Acquired And Ventilator-Associated Pneumonia Caused By Acinetobacter Baumannii-Calcoaceticus Complex In China

Chat with this insight

Recent Analyst Ratings for $INVA$ZLAB

$INVA$ZLAB Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Smiley Joshua L bought $64,200 worth of American Depositary Shares (3,000 units at $21.40), increasing direct ownership by 10% to 31,684 units (SEC Form 4)

Smiley Joshua L bought $62,490 worth of American Depositary Shares (3,000 units at $20.83), increasing direct ownership by 15% to 23,527 units (SEC Form 4)

Smiley Joshua L bought $119,600 worth of American Depositary Shares (4,000 units at $29.90), increasing direct ownership by 24% to 20,527 units (SEC Form 4)

$INVA$ZLAB Press Releases

Fastest customizable press release news feed in the world

Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)

Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares

Zai Lab Announces Pricing of Public Offering of American Depositary Shares

$INVA$ZLAB SEC Filings

SEC Form 8-K filed by Zai Lab Limited

SEC Form 424B5 filed by Zai Lab Limited

SEC Form 424B5 filed by Zai Lab Limited

$INVA$ZLAB Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by Innoviva Inc.

SEC Form SC 13G filed by Zai Lab Limited

Amendment: SEC Form SC 13G/A filed by Zai Lab Limited

$INVA$ZLAB Leadership Updates

Live Leadership Updates

Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D

Innoviva Appoints Stephen Basso as Chief Financial Officer

Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics

$INVA$ZLAB Financials

Live finance-specific insights

$INVA$ZLAB Market Insights

Live Market Insights

$INVA$ZLAB Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates

Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress

ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer

Zai Lab And argenx Get Approval For Efgartigimod Alfa SC Injection For Generalized Myasthenia Gravis In China

JP Morgan Maintains Overweight on Zai Lab, Lowers Price Target to $38

Chief Accounting Officer Zhen Marianne was granted 300 shares and covered exercise/tax liability with 976 shares, decreasing direct ownership by 1% to 44,939 units (SEC Form 4)

Chief Financial Officer Chen Yajing converted options into 500 units of American Depositary Shares and sold $5,121 worth of American Depositary Shares (167 units at $30.66), increasing direct ownership by 2% to 15,494 units (SEC Form 4)

Chief Financial Officer Chen Yajing converted options into 920 units of American Depositary Shares and sold $7,645 worth of American Depositary Shares (301 units at $25.40), increasing direct ownership by 4% to 15,161 units (SEC Form 4)

$INVA$ZLAB Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Cantor Fitzgerald initiated coverage on Innoviva

Morgan Stanley initiated coverage on Zai Lab with a new price target

Cantor Fitzgerald initiated coverage on Zai Lab with a new price target

Recent Analyst Ratings for
$INVA
$ZLAB

$INVA
$ZLAB
Insider Purchases

$INVA
$ZLAB
Press Releases

$INVA
$ZLAB
SEC Filings

$INVA
$ZLAB
Large Ownership Changes

$INVA
$ZLAB
Leadership Updates

$INVA
$ZLAB
Financials

$INVA
$ZLAB
Market Insights

$INVA
$ZLAB
Insider Trading

$INVA
$ZLAB
Analyst Ratings